The peptide αCT1 reduced collagen alignment in surgical scars to resemble unwounded skin, correlating with a 47% improvement in scar appearance seen in Phase II clinical trials.
47% scar improvementPhase II clinical trials showed nearly half the scar appearance improvement at 9 months following a single acute treatment with αCT1 peptide
What the researchers found
αCT1-treated scars showed significantly less collagen fiber alignment compared to vehicle-control treated wounds within the same patient at 29 days post-wounding — a pattern resembling unwounded skin rather than typical scar tissue.
The mechanism was traced to αCT1 causing decreased directionality of fibroblast movement during wound closure, which was demonstrated in both mouse and human fibroblast scratch wound assays. An agent-based computational model parameterized with the motility data successfully predicted the collagen alignment patterns observed in human and animal experiments. Phase II clinical trials had previously reported 47% improvement in scar appearance at 9 months post-surgery.
Why it matters
Scarring is a major clinical problem affecting tens of millions of people annually after surgeries and injuries. Current scar treatments are largely limited to silicone sheets and steroid injections with modest efficacy. A peptide that fundamentally changes how collagen is deposited during healing — making scars structurally resemble normal skin — represents a mechanistically novel approach with demonstrated clinical benefit.
The numbers in context
47% scar improvement (Phase II, 9mo); less collagen alignment; faster closure; decreased directionality; targets Cx43 and ZO-1
How the study worked
Multi-level investigation combining: (1) Phase I clinical trial biopsies comparing αCT1 vs. vehicle-treated wounds within the same patient at 29 days; (2) animal model replication in Sprague-Dawley rats and IAF hairless guinea pigs; (3) in vitro scratch wound assays with NIH 3T3 mouse fibroblasts and primary human dermal fibroblasts; (4) agent-based computational modeling to predict collagen organization from fibroblast motility data.
Who was studied
Phase I surgical wound patients; Sprague-Dawley rats; IAF hairless guinea pigs
What this study cannot tell us
Phase I biopsies were taken at 29 days, which captures early scar remodeling but not the full maturation process. Clinical sample sizes were small. Animal models, while confirmatory, do not perfectly replicate human scarring biology. The computational model makes simplifying assumptions about fibroblast behavior. Long-term collagen remodeling dynamics were not fully characterized.
How to read the evidence
This study combines Phase I clinical biopsy data, animal model validation, in vitro mechanistic experiments, and computational modeling, supported by prior Phase II clinical results. The multi-level evidence with clinical data represents a strong evidence base for a peptide therapeutic.
When this study was published
Published in 2021, this study builds on a pipeline that has been in clinical development for several years. The underlying Phase II efficacy data predates this mechanistic investigation.
The bigger picture
Connexin 43 is a gap junction protein found in many tissues. The discovery that a peptide mimicking its carboxyl terminus can modulate wound healing opened a new therapeutic area. αCT1 is notable because it has progressed from basic science through Phase II clinical trials — a rare achievement for a peptide-based wound healing therapeutic. The mechanistic insight that scar quality depends on fibroblast movement patterns, not just quantity, could inform broader wound healing research.
Questions still open
- Would αCT1 be effective for treating existing mature scars, or only during the initial wound healing period?
- Can the αCT1 mechanism be applied to other types of fibrosis beyond skin, such as cardiac or liver fibrosis?
- What is the optimal treatment window and dosing regimen for maximizing scar quality improvement?
Common questions
How does αCT1 make scars look more like normal skin?
Is αCT1 available for clinical use?
Read the original research
The connexin 43 carboxyl terminal mimetic peptide αCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(8), e21762
Citation
Montgomery, Jade; Richardson, William J; Marsh, Spencer; Rhett, J Matthew; Bustos, Francis; Degen, Katherine; Ghatnekar, Gautam S; Grek, Christina L; Jourdan, L Jane; Holmes, Jeffrey W; Gourdie, Robert G. (2021). The connexin 43 carboxyl terminal mimetic peptide αCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(8), e21762. https://doi.org/10.1096/fj.202001881R